WO2011102626A3 - 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용 - Google Patents

폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용 Download PDF

Info

Publication number
WO2011102626A3
WO2011102626A3 PCT/KR2011/000977 KR2011000977W WO2011102626A3 WO 2011102626 A3 WO2011102626 A3 WO 2011102626A3 KR 2011000977 W KR2011000977 W KR 2011000977W WO 2011102626 A3 WO2011102626 A3 WO 2011102626A3
Authority
WO
WIPO (PCT)
Prior art keywords
production method
polyazamacrocyclic compound
use therefor
biomedical use
polyazamacrocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/000977
Other languages
English (en)
French (fr)
Other versions
WO2011102626A2 (ko
Inventor
유정수
판댜달판
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of KNU
Original Assignee
Industry Academic Cooperation Foundation of KNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of KNU filed Critical Industry Academic Cooperation Foundation of KNU
Priority to US13/521,177 priority Critical patent/US9079867B2/en
Priority to EP11744868.8A priority patent/EP2537834B1/en
Publication of WO2011102626A2 publication Critical patent/WO2011102626A2/ko
Publication of WO2011102626A3 publication Critical patent/WO2011102626A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명에 따라 이작용기성 킬레이트제(BFC)로서 유용한 신규의 폴리아자마크로사이클릭 화합물을 선택적이며 높은 수율로 합성할 수 있다. 합성된 신규의 폴리아자마크로사이클릭 화합물은 금속에 킬레이트되어 펩티드 등의 생활성(bioactive) 분자와 컨쥬게이션될 수 있으며, 질환의 치료 및 진단에 응용될 수 있다.
PCT/KR2011/000977 2010-02-16 2011-02-14 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용 Ceased WO2011102626A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/521,177 US9079867B2 (en) 2010-02-16 2011-02-14 Polyazamacrocyclic compound, and a production method and a biomedical use therefor
EP11744868.8A EP2537834B1 (en) 2010-02-16 2011-02-14 Polyazamacrocyclic compound, and a production method and a biomedical use therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2010-0013781 2010-02-16
KR20100013781 2010-02-16
KR10-2011-0010062 2011-02-01
KR1020110010062A KR101253100B1 (ko) 2010-02-16 2011-02-01 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용

Publications (2)

Publication Number Publication Date
WO2011102626A2 WO2011102626A2 (ko) 2011-08-25
WO2011102626A3 true WO2011102626A3 (ko) 2012-01-19

Family

ID=44931020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/000977 Ceased WO2011102626A2 (ko) 2010-02-16 2011-02-14 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용

Country Status (4)

Country Link
US (1) US9079867B2 (ko)
EP (1) EP2537834B1 (ko)
KR (1) KR101253100B1 (ko)
WO (1) WO2011102626A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230031576A1 (en) * 2019-11-08 2023-02-02 The University Of Queensland Radiolabelled targeting ligands
US20250205372A1 (en) * 2022-03-18 2025-06-26 The Research Foundation For The State University Of New York Radiopharmaceutical compositions, synthetic methods, and methods of treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065266A2 (en) * 2004-04-20 2006-06-22 Dendritic Nanotechnologies, Inc. Dendritic polymers with enhanced amplification and interior functionality
WO2009143101A2 (en) * 2008-05-19 2009-11-26 Bracco Imaging S.P.A. Gastrin releasing peptide compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
JPH0720989B2 (ja) * 1988-05-25 1995-03-08 アメリカ合衆国 大環状キレート化合物の抱合体と診断的テスト方法
CA1341373C (en) * 1988-06-24 2002-07-02 Roberta C. Cheng Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
IT1291624B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
IT1292131B1 (it) * 1997-06-11 1999-01-25 Bracco Spa Processo per la preparazione di 5h,9bh-2a,4a,7,9a-ottaidrotetraaza- ciclootta(cd)pentalene
IT1293778B1 (it) * 1997-07-25 1999-03-10 Bracco Spa 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
WO2005003105A1 (en) * 2003-07-08 2005-01-13 The University Of Hong Kong Synthesis of tris n-alkylated 1,4,7,10-tetraazacyclododecanes
JP2007516288A (ja) * 2003-12-23 2007-06-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 金属キレート剤として有用な新規化合物
WO2006002873A2 (en) * 2004-07-02 2006-01-12 Bracco Imaging Spa 1 , 4 -bis (carboxymethyl) -6- ' bis ( carboxymethyl) amino ! -6 -methyl- perhydro-1 , 4 diazepine (aazta) derivatives as ligands in high relaxivity contrast agents for use in magnetic resonance imaging (mri )
NO20051911D0 (no) * 2005-04-19 2005-04-19 Amersham Health As Synthesis
WO2008073828A2 (en) * 2006-12-08 2008-06-19 Northwestern University Compositions and methods for magnetic resonance imaging contrast agents
US20120095185A1 (en) 2010-09-20 2012-04-19 Nordion (Canada) Inc. Process for chelating copper ions using cb-te2a bifunctional chelate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065266A2 (en) * 2004-04-20 2006-06-22 Dendritic Nanotechnologies, Inc. Dendritic polymers with enhanced amplification and interior functionality
WO2009143101A2 (en) * 2008-05-19 2009-11-26 Bracco Imaging S.P.A. Gastrin releasing peptide compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KARFELD, LINSAY S. ET AL.: "Use of a Genetically Engineered Protein for the Design of a Multivalent MRI Contrast Agent", BIOCONJUGATE CHEMISTRY, vol. 18, no. 6, 2007, pages 1697 - 1700, XP009106214, DOI: doi:10.1021/bc700149u *
KIM, JASON S. ET AL.: "Self-Assembled Hybrid Nanoparticles for Cancer-Specific Multimodal Imaging", J. AM. CHEM. SOC., vol. 129, 2007, pages 8962 - 8963, XP055072575, DOI: doi:10.1021/ja073062z *
LIU, SHUANG ET AL.: "Comparison of Yttrium and Indium Complexes of DOTA-BA and DOTA-MBA: Models for 90Y- and 111In-Labled DOTA-Biomolecules Conjugates", BIOCONJUGATE CHEMISTRY, vol. 13, 2002, pages 902 - 913 *
MACHITANI, KOJI ET AL.: "Molecular Design of Tetraazamacrocyclic Derivatives Bearing a Spirobenzopyran and Three Carboxymethyl Moieties and Their Metal-I on Complexing Behavior", ANALYTICAL SCIENCES, vol. 24, 2008, pages 463 - 469, XP055072583, DOI: doi:10.2116/analsci.24.463 *
See also references of EP2537834A4 *
TU, CHUQIAO ET AL.: "Photochromically-controlled, reversibly-activated MRI and optical contrast agent", CHEM. COMMUN., 2007, pages 1331 - 1333 *

Also Published As

Publication number Publication date
EP2537834B1 (en) 2018-09-05
US20130004423A1 (en) 2013-01-03
EP2537834A4 (en) 2013-09-11
US9079867B2 (en) 2015-07-14
EP2537834A2 (en) 2012-12-26
KR101253100B1 (ko) 2013-04-10
WO2011102626A2 (ko) 2011-08-25
KR20110095143A (ko) 2011-08-24

Similar Documents

Publication Publication Date Title
PH12013501143A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
WO2012090150A3 (en) New cell-penetrating peptides and uses thereof
WO2014036445A3 (en) Novel mucolytic agents
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
IN2012DN02737A (ko)
WO2011082267A8 (en) Substituted triazolo-pyrazine compounds
MY173877A (en) Branched 3-phenylpropionic acid derivatives and the use thereof
NZ609309A (en) Redox drug derivatives
WO2011082266A3 (en) Substituted heterocyclic compounds
HK1204578A1 (en) Medicament for the treatment of acute myeloid leukemia (aml)
WO2008151749A3 (de) Aktivierbare diagnostische und therapeutische verbindung
IN2012DN02210A (ko)
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
WO2011102626A3 (ko) 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용
WO2013071400A8 (en) Apocynin-lipoic acid conjugates and uses thereof cross-reference to related applications
AU2019257492A1 (en) Novel compositions and methods for the treatment of immune related diseases
NZ609924A (en) Porphyrin treatment of neurodegenerative diseases
WO2011000945A3 (en) Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
PT2454266E (pt) Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)- 7,12,25-trioxa-19,21,24-triaza-tetraciclo- [18.3.1.1(2,5).1(14)18)]hexacosa- 1(24),2,4,9,14,16,18(26),20,22-nonaeno
WO2011127482A3 (en) Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto
MY166065A (en) Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11744868

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13521177

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011744868

Country of ref document: EP